Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate the clinical efficacy and safety of daily treatment for 12
weeks of oral administration of a delayed release, locally delivered 6MP (mercaptopurine)
drug (80 mg), as compared to standard Purinethol (at a dose of 1-1.5 mg/kg/body weight), in
alleviating the clinical, immunological and mucosal signs and symptoms of moderately active
Crohn's Disease